Biomarkers for drug development in propionic and methylmalonic acidemias

Area of Science:

• Biochemistry and Genetics
• Metabolic Disorders
• Clinical Trial Development

Background:

• Propionic acidemia (PA) and methylmalonic acidemia (MMA) are rare genetic metabolic disorders.
• There is a significant unmet need for validated biomarkers and surrogate endpoints in clinical trials for PA and MMA.
• Understanding the pathophysiology and clinical manifestations is key to identifying potential biomarkers.

Purpose of the Study:

• To review potential biomarkers and surrogate endpoints for propionic acidemia and methylmalonic acidemia.
• To examine the pathophysiological basis for proposed biomarkers in PA and MMA.
• To assess the clinical relevance of various metabolites and markers for drug development in these conditions.

Main Methods:

• Literature review of existing research on propionic acidemia and methylmalonic acidemia.
• Analysis of primary and secondary metabolites as potential biomarkers.
• Evaluation of organ damage markers and mitochondrial disease indicators.

Main Results:

• Primary metabolites like methylcitric acid (MCA), MCA:citric acid ratio, propionylcarnitine (C3), and ¹³ C-propionate oxidation show clinical relevance.
• Methylmalonic acid is a potential biomarker specifically for MMA.
• Secondary metabolites (e.g., ammonium) and fibroblast growth factor 21 are also identified as potential biomarkers.

Conclusions:

• Several metabolites and markers show promise as biomarkers for PA and MMA.
• Further research is essential to validate these potential biomarkers as surrogate endpoints for clinical trials.
• Exploring additional metabolites and organ damage markers may yield further insights for drug development.